David Ambinder, MD
David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.
Articles by David Ambinder, MD
There are 7 recommendations specific to the appropriateness of and proper technique for kidney-sparing management.
The recent AUA/SUO guideline on the management of non-metastatic UTUC includes 2 recommendations for lymph node dissection.
Drs. David Ambinder and Akhil Saji highlight the importance of attending the AUA meeting as urology residents.
A retrospective study investigated the efficacy of UGN-101 as an adjuvant therapy after complete endoscopic tumor ablation.
Dr. Ambinder interviews Dr. Scarpato on when focal therapy should be recommended as salvage therapy for BCR prostate cancer.
Is there an alternative regimen to BCG for NMIBC? The combination of intravesical gemcitabine and docetaxel may be.
The recent ProtecT analysis examined 15-year follow-up data on mortality, metastasis-free survival, and disease progression.
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
Cryotherapy as a concept has been discussed since the 2000s. Yet randomized trials for the use of focal therapy are lacking.
Can using a hyaluronic acid spacer mitigate rectal toxicity and reduce the gastrointestinal toxicity associated with RT?
Active Surveillance May Be Appropriate for Some Men With Favorable Intermediate-Risk Prostate Cancer
It is increasingly common for patients with favorable intermediate-risk PC to be managed with active surveillance.
Implementing sterilization techniques may reduce infectious complications associated with transrectal prostate biopsy.
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Cytoreductive nephrectomy is controversial in the metastatic RCC setting, especially in the age of immunotherapy.
With a lack of trials that address different surgical options for localized PC, is there evidence to guide patients?
A recent review provides evidence of room for improvement in racial, ethnic group representation in clinical trials.
Upfront cytoreductive nephrectomy for patients with MRCC with immune checkpoint inhibitors or targeted therapy is examined.
According to a recent study published in The Lancet Oncology, radiation may offer safety and long-term efficacy for RCC.
By administering immediate single-dose intravesical chemotherapy, there is a 15% absolute risk reduction in tumor recurrence.
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
670 Madison Ave.
Manalapan, NJ 07726